IndraLab
Statements
Sulfonylurea inhibits NLRP3. 27 / 27
|
27
reach
"The results confirm that the NLRP3 inflammasome and local IL-1beta (+) F4/80 (+) Ly6C (+) macrophages as novel players in the pathogenesis of VCP associated myopathy and identified the sulfonylurea MCC950 inhibitor of the NLRP3 inflammasome with promising therapeutic potential for the treatment of VCP associated myopathy."
reach
"Together, these results suggest that : (i) the NLRP3 inflammasome and local IL-1beta (+) F4/80 (+) Ly6C (+) macrophages as novel players in the pathogenesis of VCP associated myopathy; and (ii) identified the sulfonylurea MCC950 inhibitor of the NLRP3 inflammasome with promising therapeutic potential for the future treatment of patients with VCP associated myopathy."